Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Merck
McKesson
Mallinckrodt
Express Scripts

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for SUVN-502

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug SUVN-502: Patents, clinical trial progress, indications

SUVN-502 is an investigational drug.

There have been 7 clinical trials for SUVN-502. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Cognition Disorders, Depressive Disorder, Major, and Depressive Disorder. The leading clinical trial sponsors are Suven Life Sciences Limited and [disabled in preview].

There are four US patents protecting this investigational drug and ninety-eight international patents.

Recent Clinical Trials for SUVN-502
TitleSponsorPhase
A Study to Evaluate Safety, and Efficacy of SUVN-G3031 in Patients With Narcolepsy With and Without CataplexySuven Life Sciences LimitedPhase 2
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy SubjectsSuven Life Sciences LimitedPhase 1
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy SubjectsSuven Life Sciences LimitedPhase 1

See all SUVN-502 clinical trials

Clinical Trial Summary for SUVN-502

Top disease conditions for SUVN-502
Top clinical trial sponsors for SUVN-502

See all SUVN-502 clinical trials

US Patents for SUVN-502

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SUVN-502   See Pricing Active metabolite of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-- 1H-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite SUVEN SCIENCES LIMITED (Hyderabad, Andhra, IN)   See Pricing
SUVN-502   See Pricing Tetracyclic 3-substituted indoles having serotonin receptor affinity Suven Life Sciences Limited (Hyderabad, Adhra Pradesh, IN)   See Pricing
SUVN-502   See Pricing N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them Suven Life Sciences Limited (IN)   See Pricing
SUVN-502   See Pricing Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-- 1H-indole dimesylate monohydrate SUVEN LIFE SCIENCES LIMITED (Hyderbad, IN)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SUVN-502

Drugname Country Document Number Estimated Expiration Related US Patent
SUVN-502 Australia 2014404000 1989-12-31   See Pricing
SUVN-502 Brazil 112017002921 1989-12-31   See Pricing
SUVN-502 Canada 2957497 1989-12-31   See Pricing
SUVN-502 China 106794170 1989-12-31   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
McKinsey
Colorcon
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.